Back to search results
The primary objectives of this study are to evaluate the safety, tolerability, and
pharmacokinetics (PK) of remdesivir (RDV) in participants with laboratory-confirmed
coronavirus disease 2019 (COVID-19) aged 0 days to < 18 years.
Status: Open/Actively Recruiting